A study published last Sunday in the New England Journal of Medicine is receiving ample response from omega-3 industry organizations. Using a population cohort of nearly 5,000 people who supplemented with omega-3-enriched margerines for 40 months, researchers behind the study concluded that 'Low doses of omega-3 fatty acids did not significantly reduce the rates of cardiovascular end points.' This was determined to be the case with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA).
A study published last Sunday in the New England Journal of Medicine is receiving ample response from omega-3 industry organizations.
Using a population cohort of nearly 5,000 people who supplemented with omega-3-enriched margerines for 40 months, researchers behind the study concluded that 'Low doses of omega-3 fatty acids did not significantly reduce the rates of cardiovascular end points.'ÃÂ This was determined to be the case with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA).
The Global Organization for EPA and DHA Omega-3 (GOED; Salt Lake City) has since responded to the study, noting several factors that may have influenced the negative results.
'The study...s authors have stated that such findings may have been affected by multiple unique variables, most notable the administration of cholesterol- and blood pressure-lowering treatments to all subjects during the study...s duration,'ÃÂ said GOED in a recent press release.
GOED also cites the 'relatively low daily dose'ÃÂ of EPA and DHA which was used. 'While 400 mg of combined EPA/DHA provides a sufficient dose for most healthy individuals, previous clinical studies in individuals having suffered a heart attack suggest that 1,000 mg+ of EPA/DHA decreases the incidence of secondary cardiovascular,'ÃÂ said GOED.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.